A Description Of Real-World Treatment With Abiraterone Acetate In Metastatic Castration-Resistant Prostate Cancer Patients In The Post-Chemotherapy Setting In France And The Netherlands

Abstract

A435 1.352) and 0.385(0.248; 0.596) respectively for OS and PFS. Survival extrapolation provided estimates of 8 month of additional OS gain for Lenvatinib vs. sorafenib, with MAIC extrapolation showing largest gain and a good model fit. ConClusions: This analysis demonstrated that in absence of head-to-head trials, MAIC is an important methodology to adjust for population and trial differences, especially in orphan diseases where limited data are available. MAIC can increase reliability of comparativeeffectiveness data and support payers decision making.

Efficacy of abiraterone acetate in castration‐resistant metastatic prostate cancer: A real‐world data analysis

“…were inconsistent with the previous reports, including the phase III randomized controlled clinical trials, [15][16][17][18] concluding a longer survival for CT-naive patients. Several studies have shown that the ECOG PS of 2 and above was associated with poor prognosis in both pre-and post-CT series.…”